Welcome to our dedicated page for Kala Pharmaceuticals SEC filings (Ticker: KALA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The KALA BIO, Inc. (NASDAQ: KALA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into KALA’s clinical-stage biopharmaceutical business focused on rare and severe eye diseases, its mesenchymal stem cell secretome (MSC-S) platform, and its evolving financial and strategic position.
Through KALA’s annual reports on Form 10-K and quarterly reports on Form 10-Q, investors can review information on research and development activities, pipeline programs such as KPI-012 and KPI-014, risk factors, liquidity and capital resources. Current Reports on Form 8-K highlight material events, including the CHASE Phase 2b trial results for KPI-012, decisions to cease development of KPI-012 and the MSC-S platform, workforce reductions, financing agreements, loan defaults and settlements with Oxford Finance LLC, and Nasdaq listing deficiency notices.
KALA’s filings also include transaction-related documents, such as the Securities Purchase Agreement for Series AA and Series AAA convertible preferred stock, the Convertible Loan Agreement with an investor, and the Oxford Loan Settlement Agreement. These records explain how the company has structured recent financings, addressed debt obligations and framed its exploration of strategic alternatives. Notifications like Form 12b-25 describe timing of periodic reports when delays occur.
On Stock Titan, KALA filings are updated in near real time as they appear on EDGAR. AI-powered summaries help interpret lengthy 10-K and 10-Q reports, breaking down key sections on clinical programs, cash runway, going-concern language and risk disclosures. For Form 4 and other insider-related filings, users can quickly see reported insider transactions in KALA stock. This combination of raw filings and AI-generated explanations allows readers to understand what each document means for KALA’s business, capital structure and potential strategic direction without having to parse every page manually.
KALA BIO, INC. notifies the SEC it cannot timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and expects to file within the 15-calendar-day extension period.
The company cites significant director and officer turnover and a strategic business transition that began in November 2025, requiring additional time to compile, analyze and audit supporting documentation. Preliminary results show an anticipated 2025 net loss of $27.3 million, versus $38.5 million in 2024; the company attributes the change to remeasurement gains, debt extinguishment and lower R&D, partially offset by higher G&A. The figures remain subject to year-end closing and audit.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice listing multiple blocks of restricted common stock tied to specific grant/vesting dates. The filing lists individual lot sizes such as 2,450 shares (01/30/2026), 2,662 shares (06/22/2024 and 06/22/2025), and several smaller lots dated between 06/11/2024 and 06/17/2021.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting proposed sales of restricted Common Stock of KALA. The notice lists multiple restricted-stock lots with specific lot sizes and grant/vesting dates, including 01/30/2026 (2,450 shares) and 06/11/2025 (1,400 shares).
The filing lists additional restricted-stock lots (e.g., 397; 1,261; 800; 222; 221; 1,100 shares) tied to grant or restriction dates shown in the table. The filing is a broker notice of proposed sales under Rule 144; timing and aggregate proceeds are not stated in the provided excerpt.
KALA BIO entered a Platform Development and Exclusive License Agreement with Younet AI, securing a worldwide exclusive license to the Researgency biomedical AI research platform for an initial 12‑month term, with options for successive one‑year renewals. KALA will pay up to $530,000 in cash during the initial term and issue 5,000,000 shares of common stock to Younet, with each renewal triggering an additional $250,000 in cash and 5,000,000 shares. Younet agreed not to sell more than 3% of daily trading volume in its shares on any trading day, except for certain block trades. KALA also obtained an irrevocable option to acquire all of Younet’s equity or substantially all of its assets for $55,000,000. The company plans to use Researgency first on its own datasets, then to build an on‑premises AI infrastructure platform offered to biotech and pharmaceutical clients on a subscription basis.
KALA BIO, Inc. reported that on February 16, 2026, director David Lazar resigned from the company’s Board of Directors, effective the same day. The company stated that Mr. Lazar’s resignation was not related to any disagreement with KALA BIO regarding its operations, policies, or practices. The filing is a governance update and does not describe any accompanying strategic or financial changes.
KALA BIO, Inc. is registering up to 241,435,910 shares of common stock for resale by existing stockholders, including 238,335,910 shares issued or issuable upon conversion of preferred stock plus shares issued under settlement agreements with LifeSci Capital and Baker Brothers funds. This is a resale registration only, so KALA will not receive proceeds from any share sales, while it will cover registration expenses and selling stockholders will pay any selling commissions.
The shares were largely created through a $6.0 million private placement of Series AA and Series AAA preferred stock and through equity-based settlements of advisory and participation-rights disputes. As of February 4, 2026, 911,330,225 common shares were outstanding.
KALA highlights significant listing risk: Nasdaq has notified the company that it is below the $35 million market value of listed securities requirement, with a compliance deadline of May 11, 2026, and below the $1.00 minimum bid price requirement, with a compliance period through July 20, 2026. Failure to regain compliance could lead to delisting, reduced liquidity, penny-stock status and greater difficulty raising capital.
Baker Bros. Advisors and affiliates report a 9.99% beneficial stake in KALA BIO, Inc. They disclose beneficial ownership of 2,890,055 shares of common stock, including 1,086,000 shares issuable upon conversion of 10,860 shares of Series G non-voting convertible preferred stock.
The ownership calculation uses 27,849,725 KALA common shares outstanding as of December 31, 2025, plus the Series G convertible shares. The filing notes a “Beneficial Ownership Limitation” that generally caps the group’s ownership at 9.99% of KALA’s outstanding common stock for conversion purposes.
The preferred stock series (E, F, G and H) are each convertible into common stock on a 1‑for‑100 basis without additional consideration, but only to the extent conversion does not breach the ownership cap. The funds may adjust this cap up to 19.99%, with any increase becoming effective on the 61st day after notice to KALA.
KALA BIO, Inc. files a resale registration covering up to 241,435,910 shares of common stock for existing stockholders. The shares include 238,335,910 shares from preferred stock conversions, 2,200,000 shares issued to LifeSci Capital LLC, and 900,000 settlement shares issued to Baker Brothers entities.
All shares may be sold from time to time by the selling stockholders, and KALA will not receive any proceeds from these sales, though it will pay registration expenses. As context, 911,330,225 shares of common stock were outstanding as of February 4, 2026. The filing also highlights Nasdaq notices that KALA is currently below market‑value and minimum bid‑price listing requirements, creating a risk of potential delisting if compliance is not regained.
KALA BIO director Brendan P. Purdy filed an initial ownership report stating he currently holds no company securities. The Form 3 identifies him as a director of KALA BIO, Inc. and confirms that no non-derivative or derivative securities are beneficially owned as of the reported event date.
The filing also notes that a power of attorney authorizes Avraham Minkowitz to sign and submit the report on Purdy’s behalf.